 HAIFA, Israel, Dec. 29, 2020 GLOBE NEWSWIRE -- Pluristem Therapeutics Inc. Nasdaq:PSTI TASE:PSTI, a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today it has entered into a collaboration agreement with Mexican pharmaceutical company Innovare RD to expand its ongoing clinical program of PLX cells in the treatment of Acute Respiratory Distress Syndrome ARDS associated with COVID-19 in Mexico. The Phase II study in Mexico is subject to the approval of local authorities, with the goal of being conducted under the U.S. Food and Drug Administration FDA cleared protocol . 